126 related articles for article (PubMed ID: 36099749)
1. Development of l-Dopa-containing diketopiperazines as blood-brain barrier shuttle.
Cornacchia C; Marinelli L; Di Rienzo A; Dimmito MP; Serra F; Di Biase G; De Filippis B; Turkez H; Mardinoglu A; Bellezza I; Di Stefano A; Cacciatore I
Eur J Med Chem; 2022 Dec; 243():114746. PubMed ID: 36099749
[TBL] [Abstract][Full Text] [Related]
2. Diketopiperazines as a tool for the study of transport across the blood-brain barrier (BBB) and their potential use as BBB-shuttles.
Teixidó M; Zurita E; Malakoutikhah M; Tarragó T; Giralt E
J Am Chem Soc; 2007 Sep; 129(38):11802-13. PubMed ID: 17764181
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Colamartino M; Santoro M; Duranti G; Sabatini S; Ceci R; Testa A; Padua L; Cozzi R
Neurotox Res; 2015 Feb; 27(2):106-17. PubMed ID: 25355370
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents.
Di Stefano A; Marinelli L; Eusepi P; Ciulla M; Fulle S; Di Filippo ES; Magliulo L; Di Biase G; Cacciatore I
Biomolecules; 2019 Jun; 9(6):. PubMed ID: 31216771
[TBL] [Abstract][Full Text] [Related]
5. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
[TBL] [Abstract][Full Text] [Related]
6. New diketopiperazines as vectors for peptide protection and brain delivery: Synthesis and biological evaluation.
Virgone-Carlotta A; Dufour E; Bacot S; Ahmadi M; Cornou M; Moni L; Garcia J; Chierici S; Garin D; Marti-Batlle D; Perret P; Ghersi-Egea JF; Moulin Sallanon M; Fagret D; Ghezzi C
J Labelled Comp Radiopharm; 2016 Oct; 59(12):517-530. PubMed ID: 27611733
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis?
Scigliano G; Girotti F; Soliveri P; Musicco M; Radice D; Caraceni T
Ital J Neurol Sci; 1997 Apr; 18(2):69-72. PubMed ID: 9239525
[TBL] [Abstract][Full Text] [Related]
8. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Minelli A; Conte C; Prudenzi E; Cacciatore I; Cornacchia C; Taha E; Pinnen F
Free Radic Biol Med; 2010 Jul; 49(1):31-9. PubMed ID: 20307650
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of farnesene against hydrogen peroxide-induced neurotoxicity in vitro.
Turkez H; Sozio P; Geyikoglu F; Tatar A; Hacimuftuoglu A; Di Stefano A
Cell Mol Neurobiol; 2014 Jan; 34(1):101-11. PubMed ID: 24105026
[TBL] [Abstract][Full Text] [Related]
11. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Cornetta T; Palma S; Aprile I; Padua L; Tonali P; Testa A; Cozzi R
Cell Biol Toxicol; 2009 Aug; 25(4):321-30. PubMed ID: 18523852
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Mei M; Zhou Y; Liu M; Zhao F; Wang C; Ding J; Lu M; Hu G
Neuropharmacology; 2019 Dec; 160():107758. PubMed ID: 31494143
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
15. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
16. Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.
Sabens EA; Distler AM; Mieyal JJ
Biochemistry; 2010 Mar; 49(12):2715-24. PubMed ID: 20141169
[TBL] [Abstract][Full Text] [Related]
17. Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39.
Zhong SY; Chen YX; Fang M; Zhu XL; Zhao YX; Liu XY
PLoS One; 2014; 9(4):e95387. PubMed ID: 24743653
[TBL] [Abstract][Full Text] [Related]
18. Zingiberene attenuates hydrogen peroxide-induced toxicity in neuronal cells.
Togar B; Türkez H; Stefano AD; Tatar A; Cetin D
Hum Exp Toxicol; 2015 Feb; 34(2):135-44. PubMed ID: 24925361
[TBL] [Abstract][Full Text] [Related]
19. New Blood-Brain Barrier Models Using Primary Parkinson's Disease Rat Brain Endothelial Cells and Astrocytes for the Development of Central Nervous System Drug Delivery Systems.
Cai P; Zheng Y; Sun Y; Zhang C; Zhang Q; Liu Q
ACS Chem Neurosci; 2021 Oct; 12(20):3829-3837. PubMed ID: 34623131
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson's Disease.
Mogharbel BF; Cardoso MA; Irioda AC; Stricker PEF; Slompo RC; Appel JM; de Oliveira NB; Perussolo MC; Saçaki CS; da Rosa NN; Dziedzic DSM; Travelet C; Halila S; Borsali R; de Carvalho KAT
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
